Understanding Long COVID
Long COVID, or post-acute COVID-19 syndrome, refers to lingering symptoms and complications lasting beyond four weeks after the initial infection. Research shows that 50–80% of individuals who recover from COVID-19 experience persistent effects such as fatigue, body aches, shortness of breath, difficulty concentrating, headaches, and loss of taste or smell. These symptoms can significantly affect daily activities and quality of life.

How MSC Therapy May Help
Mesenchymal Stem Cells (MSCs), particularly those derived from umbilical cord tissue, have been studied for their potential to:

• Reduce Inflammation: MSCs migrate to inflamed or damaged tissues, releasing factors that lower chronic inflammation.
• Support Immune Regulation: By modulating immune responses, MSCs can help prevent excessive cytokine activity.
• Promote Tissue Repair: MSCs can aid in regenerating damaged lung, nerve, or other tissues affected by the virus.

Expected Benefits
Patients undergoing MSC therapy for Long COVID may experience:

• Faster Recovery Times – Improved energy levels and reduced fatigue.
• Symptom Relief – Decreased shortness of breath, headaches, and muscle aches.
• Better Quality of Life – Enhanced focus, improved taste/smell, and overall functional well-being.

MSC therapy represents a promising option for managing Long COVID by targeting inflammation, regulating the immune system, and promoting tissue repair, ultimately helping patients regain their health and vitality.